Home > Products > CD64 & EGFR
> Recombinant Anti-CD64 x Anti-EGFR VHH BispecificAntibody (Bibody)
Recombinant Anti-CD64 x Anti-EGFR VHH BispecificAntibody (Bibody) (CAT#: BIBD-391)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Bibody) is a Fab-VHH format that uses heterodimeric Fab as a scaffold, and a VHH region linked to one of its heavy (Fd) or light (L) chain. The VHH of the anti-EGFR specificity is fused to the anti-CD64 heavy or light chain of the Fab. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-EGFR VHH BispecificAntibody (Bibody) (BIBD-391). Click the button below to contact us or submit your feedback about this product.